EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudie

Efficacy and Safety of Desidustat Versus Erythropoietin in Post Kidney Transplant Anaemia: A Prospective Observational Study

Pooja Barak, Smita Divyaveer iD, Smita Pattanaik, Sahil Kharbanda, Prasanna Ethiraj S, Vignesh Subramani, Rajesh Kumar, Kushal Kekan, Simran Behl, Madhuri Kashyap, Kanchan Prajapati, Deepy Zohmangaihi und 8 weitere

Nephrology · 2026-04 · 31 (4)

DOI: 10.1111/nep.70201 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Nephrology, online erschienen am 07.04.2026. Verfasst von Pooja Barak und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Post Graduate Institute of Medical Education and Research, Chandigarh, India. Hauptthemen laut MEDLINE: Anemia, Erythropoietin, Hematinics, Kidney Transplantation. Die Arbeit nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Post‐renal transplant anaemia significantly impacts patient outcomes and quality of life. The only option available until recently was erythropoietin (EPO) that requires intravenous or subcutaneous injection. New class of drugs that are hypoxia‐inducible factor prolyl hydroxylase inhibitor (HIF‐PHI) (desidustat) have become available and there is scarce data on their use in kidney transplant recipients (KTRs).

Methods

This was a prospective observational study which included 58 renal transplant recipients with anaemia (Hb < 10 g/dL) who were started on either oral HIF‐PHI in the form of desidustat ( n = 30) or EPO ( n = 28) based on nephrologist discretion. Adult KTRs with a haemoglobin (Hb) level of less than 10 g/dL were included. Patients with acute graft dysfunction, bleeding and primary haematological diseases were excluded. Baseline clinical characteristics were recorded. Primary outcomes were change in Hb at 8 weeks in the two groups. Secondary outcomes included inflammatory markers (CRP, ESR), iron indices and safety.

Results

Both desidustat and erythropoietin groups showed significant improvement in Hb from baseline to 2 months (desidustat: 8.69 ± 0.86 to 9.89 ± 0.92 g/dL; EPO: 8.54 ± 0.73 to 9.55 ± 0.71 g/dL; p > 0.05). No significant differences were observed in inflammatory markers or iron indices. Both treatments were well‐tolerated, with no reported adverse events.

Conclusion

Treatment with desidustat resulted in improvement in haemoglobin levels with acceptable tolerability over short‐term follow‐up similar to erythropoietin. The convenience of oral administration supports its potential role as a patient‐centred option for anaemia management following kidney transplantation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnemiaErythropoietinHematinicsKidney TransplantationPyrazolesTriazolesAdultFemaleHumansMaleMiddle AgedBiomarkersHemoglobinsHypoxia-Inducible Factor-Proline DioxygenasesProspective StudiesTime FactorsTreatment Outcome

Stichwörter der Autor:innen

HIF‐PHIanaemiadesidustaterythropoietinkidney transplant

Substanzen

BiomarkersErythropoietinHematinicsHemoglobinsHypoxia-Inducible Factor-Proline DioxygenasesPyrazolesTriazoles

Autor:innen und Institutionen

  • Department of Nephrology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of Biochemistry, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of Hematology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
  • Division of Hematology, Department of Medicine, University of British Columbia, Vancouver, Canada.
  • Department of Hepatology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.

ORCID-Profile: Smita Divyaveer, Nabhajit Mallik, Deepesh Lad, Madhumita Premkumar, Urmila Anandh

Zitieren

APA

Barak, P., Divyaveer, S., Pattanaik, S., Kharbanda, S., S, P. E., Subramani, V., Kumar, R., Kekan, K., Behl, S., Kashyap, M., Prajapati, K., Zohmangaihi, D., Mallik, N., Lad, D., Premkumar, M., Yadav, R., Kaur, M., Anandh, U., Ramachandran, R., & Kohli, H. S. (2026). Efficacy and Safety of Desidustat Versus Erythropoietin in Post Kidney Transplant Anaemia: A Prospective Observational Study. Nephrology, 31(4). https://doi.org/10.1111/nep.70201

Vancouver

Barak P, Divyaveer S, Pattanaik S, Kharbanda S, S PE, Subramani V, et al. Efficacy and Safety of Desidustat Versus Erythropoietin in Post Kidney Transplant Anaemia: A Prospective Observational Study. Nephrology. 2026;31(4). doi:10.1111/nep.70201

BibTeX
@article{Barak2026,
  author = {Barak, Pooja and Divyaveer, Smita and Pattanaik, Smita and Kharbanda, Sahil and S, Prasanna Ethiraj and Subramani, Vignesh and Kumar, Rajesh and Kekan, Kushal and Behl, Simran and Kashyap, Madhuri and Prajapati, Kanchan and Zohmangaihi, Deepy and Mallik, Nabhajit and Lad, Deepesh and Premkumar, Madhumita and Yadav, Rahul and Kaur, Maninder and Anandh, Urmila and Ramachandran, Raja and Kohli, Harbir Singh},
  title = {Efficacy and Safety of Desidustat Versus Erythropoietin in Post Kidney Transplant Anaemia: A Prospective Observational Study},
  journal = {Nephrology},
  year = {2026},
  volume = {31},
  number = {4},
  doi = {10.1111/nep.70201}
}
Kostenlos starten →